---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-026714"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2025-03-21T23:59:59+00:00"
generated_at: "2026-05-24T08:39:11.140210+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio reports Q4/FY2024 results; launches Phase 3 AD trial with data expected mid-2026

## Summary
- Q4 net loss $0.43/share vs $2.24 YoY; FY net loss $2.02 basic, $2.31 diluted vs $6.23 in 2023.
- Cash $10.6M at Dec 31, 2024; after $21M stock offering, runway extends to Q4 2025.
- Phase 3 early AD trial launched Feb 2025; symptomatic data expected mid-2026, disease-modifying data mid-2027.
- FDA cleared Phase 3 early AD trial Oct 2024 based on Phase 2/3 data showing symptomatic improvement.

## SEC filing metadata
- accession: 0001104659-25-026714
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2025-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465925026714/0001104659-25-026714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465925026714/tm2510031d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-026714
- JSON: https://secwatch.observer/filing/0001104659-25-026714.json
- Plain text: https://secwatch.observer/filing/0001104659-25-026714.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.